HCA Healthcare, Inc. Q3 FY2026 earnings call

• Demand and Volume Trends: The company reported its 22nd consecutive quarter of volume growth. Core demand remains strong, driven by population growth, aging demographics, and chronic conditions. ER visits surged 5.1%, indicating robust underlying demand despite elective softness.
• Payer Mix Headwinds: There is significant pressure from patients losing health insurance exchange coverage, migrating almost one-for-one to uninsured status. This migration accounts for ~80% of uninsured volume growth. While exchange volumes showed an 8% sequential improvement from Q2 to Q3, they remain significantly below prior-year levels.
• Medicaid Supplemental Payments: The company recognized a modest incremental net benefit of $50 million in Q3. Full-year 2026 benefits are now expected to be between $600 million and $800 million, driven by grandfathered programs in Virginia and other states.
• Cost Resilience Program: An enterprise-wide resiliency program is yielding results, with costs improving 40 basis points sequentially. Key focus areas include revenue integrity, asset optimization (patient flow), variable cost management (labor/supplies), and fixed cost reduction. Digital transformation and shared service expansions (e.g., Paralon) are enabling these efficiencies.
• Strategic Initiatives: HCA continues to expand its ambulatory network, nearing 3,000 units (urgent care, ASCs), to improve patient access and convenience. The company emphasizes physician engagement and clinical capability investments to support growth.
• Capital Allocation: Capital expenditures totaled ~$1.36 billion. The company repurchased ~$3 billion in shares and paid $165 million in dividends. Debt-to-Adjusted EBITDA leverage remains in the lower half of the target range.

The transcript does not provide a breakdown of financial performance by specific product segments (e.g., Inpatient vs. Outpatient) in terms of absolute revenue contribution percentages. However, it provides aggregate volume and cost metrics for the consolidated entity:

• Volume Growth: Adjusted admissions on a same-facility basis increased 3% year-over-year (YoY). Equivalent admissions grew 3%, and Emergency Room (ER) visits increased 5.1%. Conversely, inpatient surgeries declined 1.4% and outpatient surgeries declined 3.7%.
• Payer Mix Impact: Insured volumes (excluding exchanges) grew approximately 3%, while exchange-covered equivalent admissions declined approximately 19%. This shift resulted in an unfavorable impact on Adjusted EBITDA of approximately $400 million for the quarter.
• Cost Performance: Same-facility costs per equivalent admission (excluding Medicaid supplemental payments) were essentially flat YoY and improved by 40 basis points sequentially from Q2 to Q3.

• 2026 Guidance Reaffirmation: Management reaffirmed estimated guidance ranges for full-year 2026. Due to strong Q3 performance and upward revisions in Medicaid supplemental payment benefits (~$300 million increase in net benefit estimate), the company expects to finish in the upper half of its guidance ranges.
• 2027 Preliminary Outlook: Management anticipates earnings in 2027 will be generally consistent with 2026 levels. This assumes:
  • Volume growth of 2-3%.
  • A meaningful but manageable impact on payer mix, with fewer people losing exchange coverage compared to 2026.
  • No material policy changes beyond H.R. 1.
  • Continued value generation from strategic initiatives (digital transformation, network development, resiliency).
• Medicaid Payment Reduction: For 2027, the company expects to receive approximately $550 million to $650 million less in net benefits from Medicaid state supplemental payment programs due to the expiration of grandfather approvals from 2026 (primarily Florida, Virginia, Georgia).

• Payer Mix Deterioration: The continued migration of exchange-covered patients to uninsured status poses a significant headwind, estimated at $400 million unfavorable impact on Q3 Adjusted EBITDA. Full-year impact may exceed previous estimates.
• Policy Uncertainty (H.R. 1): Potential implementation of work requirements for able-bodied adults in Medicaid expansion states could impact 15-20% of the company's Medicaid body, leading to modest earnings impacts in 2027.
• Elective Surgery Softness: Elective procedures face pressure from both coverage losses (exchanges) and broader affordability concerns in the economy. Recovery timing is uncertain.
• Regulatory Changes: The phase-out of the Inpatient-Only List (IOOL) is shifting procedures to outpatient settings, impacting inpatient volumes. Additionally, proposed Medicare OPPS rules regarding 340B budget-neutral reallocations are pending finalization and legal challenges.
• Professional Fees Pressure: Professional fees (radiology and anesthesiology) rose 12% YoY and now constitute ~24% of other operating expenses, acting as a persistent cost pressure point.

Q: Analyst asked if the 2027 EBITDA consistency implies overcoming substantial exchange headwinds and if cost savings will mirror the $400M resiliency program. / A: CFO stated planning is early; core growth momentum must be validated in Q4. Exchange enrollment data (Nov-Jan) is critical for 2027 visibility. CEO noted resiliency is a strategic, ongoing agenda enabled by new tech/shared services, not a one-time event, ensuring future value creation beyond 2027.

Q: Analyst asked about the impact of the proposed Medicare OPPS rule on 340B and if flat 2027 guidance assumes any benefit. / A: CFO expressed pleasure with the proposed rule’s budget-neutral reallocation construct, which would benefit HCA. He views finalization as a positive factor for 2027 but emphasized that 'generally consistent' guidance stands until more detail is available in Q4.

Q: Analyst asked how surgical trends fit into the 2-3% volume growth forecast and if pent-up elective demand could drive upside. / A: CEO explained emergent business is strong, but elective faces macro forces like coverage and affordability. With diverse volume composition (cardiac, trauma, NICU strong), no specific surgical outlook is set yet. Q4 seasonality patterns are needed before calling out 2027 surgery trends.

Q: Analyst asked about drivers of accelerated insured revenue per unit and cost line items (SWB/OpEx). / A: CFO attributed revenue strength to strong commercial volume (+2.7%), solid rate growth, and improved contract collection via Paralon. On costs, labor was flat YoY and down 40bps sequentially due to disciplined merit adjustments and operating leverage. Professional fees remained a pressure point (+12%).

Q: Analyst asked about market positioning, potential exits, or acquisitions amidst operational pressures. / A: CEO stated HCA has intentionally pruned its portfolio over 7-8 years to optimize markets. No significant footprint changes are planned. The company remains opportunistic for new markets but focuses capital on its existing ~43 markets, leveraging outpatient expansion and physician integration to drive growth.